Helio Genomics partnered with Syneos Health to expand commercial reach of its blood-based HelioLiver test and speed adoption for early liver cancer detection.
Helio Genomics has struck a deal with Syneos Health to widen the commercial push for HelioLiver, its blood-based test for the early detection of hepatocellular carcinoma, the company said on Tuesday. The financial terms were not disclosed.
The agreement adds another distribution and sales channel for the Irvine, California-based diagnostics group, which has been steadily building access to the assay through outside partners. In 2021, Helio forged a commercial and co-branding arrangement with Fulgent Genetics, and earlier this year it began making the test available to providers linked to Quest Diagnostics.
HelioLiver uses artificial intelligence methods to analyse cell-free DNA methylation patterns, protein biomarkers and patient demographics in an effort to identify liver cancer earlier than conventional approaches. The company has also been supported by clinical and promotional claims from partners. Fulgent said in 2021 that late-breaking data showed the test outperformed alpha-fetoprotein and the GALAD model, while a later study published in the Journal of Hepatology reported better sensitivity than ultrasound in patients with cirrhosis.
Bharat Tewarie, Helio Genomics’ chief executive, said in a statement that partnering with Syneos Health marks a significant step in the company’s commercial strategy and should speed up engagement with healthcare providers nationwide. Syneos Health, a major life sciences services group, brings established commercial infrastructure that Helio is now using to expand awareness of the test beyond its existing partnerships.
The broader effort comes as liver cancer screening remains a difficult and important clinical area, with companies racing to promote blood-based tools that may complement or improve on imaging. Helio’s latest move suggests it is leaning on partners not just for distribution, but also for the sales execution needed to move a niche oncology test into wider routine use.
View source version on noah-news.com